Follicular lymphoma is considered an indolent disease, with long-term tumour control achieved by first-line ...

While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

Imugene Ltd (ASX:IMU, OTC:IUGNF) has launched a Phase 1b clinical trial at the Royal Prince Alfred Hospital in Sydney, dosing the first Australian patient with its allogeneic CAR T-cell therapy ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I TrialPatient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults LONDON, UK ...

With chemotherapy currently the main form of treatment, HG-CT-1 is based on a potentially more benign and effective CAR-T therapy, which uses and modifies a patient's own immune cells to recognize and ...

Chaturvedi, Köster et al. discuss challenges faced by studies evaluating tests for emerging infectious agents. They propose a unified framework for test development, evaluation, and validation ...

INR:1937. rummy signup bonus Phase 3 clinical trial of S1P receptor modulator jointly developed by Everest Pharmaceuticals begins with patient recruitment R&D ...

Dimerix (ASX:DXB) secured orphan drug designation for the treatment in the US and Europe, opening the door to a faster ...

INR:6263. 23 tarikh ka lottery TaiGen Biopharma's new anti-influenza drug is approved for clinical trials in the U.S., without the restriction of taking the ...

INR:7155. singam lottery apps K drug/chemotherapy combination failed in phase III clinical trial of bladder cancer Transcenta's TST001 completed first patient ...

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing ...